<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763421</url>
  </required_header>
  <id_info>
    <org_study_id>ENG_2019_01</org_study_id>
    <nct_id>NCT04763421</nct_id>
  </id_info>
  <brief_title>A Prospective, Single-Arm Multi-Center Study of the ENSEAL X1 Curved Jaw Tissue Sealer in Select Procedures</brief_title>
  <official_title>A Prospective, Single-Arm Multi-Center Study of the ENSEAL X1 Curved Jaw Tissue Sealer and Generator G11 in Upper Gastrointestinal, Lower Gastrointestinal, and Gynecological Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon Endo-Surgery</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon Endo-Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, single-arm, multi-center study will collect clinical data in a post-market&#xD;
      setting by procedure group (upper gastrointestinal [GI], lower GI, and gynecological).&#xD;
      Investigators will perform each procedure using the device in compliance with their standard&#xD;
      surgical approach and the ENSEAL X1 Curved Jaw and Generator G11 instructions for use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to demonstrate the acceptable performance and safety&#xD;
      of the ENSEAL X1 Curved Jaw and Generator G11 devices when used per the instructions for use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">October 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of Grade 3 or lower hemostasis for each vessel transection</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Grade 1: no bleeding at transection site;&#xD;
Grade 2: minor bleeding at transection site, no intervention needed;&#xD;
Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touchups with ENSEAL X1; or&#xD;
Grade 4: significant bleeding (e.g., pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or ligation with use of additional hemostatic measures (e.g., hemoclips, staples, sutures, fibrin sealants, other advanced energy products).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of 5-point scale scores for various tasks completed by the ENSEAL X1 Curved Jaw device (adhesiolysis, lymphatics or tissue bundles divided, tissue grasping, tissue cutting, or tissue dissection)</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of hemostasis grading scale for each vessel transected</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type, name, and number of additional hemostasis products required to achieve hemostasis for Grade 4 vessel transections</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Upper GI; Lower GI; Gynecological</condition>
  <arm_group>
    <arm_group_label>Upper Gastrointestinal/Lower Gastrointestinal/Gynecological</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Any upper gastrointestinal/lower gastrointestinal/gynecological procedure where the ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ENSEAL X1 Curved Jaw</intervention_name>
    <description>ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.</description>
    <arm_group_label>Upper Gastrointestinal/Lower Gastrointestinal/Gynecological</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary laparoscopic or open procedure (upper gastrointestinal, lower&#xD;
             gastrointestinal, or gynecological) where at least one vessel is planned to be&#xD;
             transected by the ENSEAL X1 Curved Jaw device per the instructions for use;&#xD;
&#xD;
          2. Willingness to give consent and comply with all study-related evaluations and visit&#xD;
             schedule; and&#xD;
&#xD;
          3. At least 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Physical or psychological condition which would impair study participation; or&#xD;
&#xD;
          2. Enrollment in a concurrent interventional clinical study that could impact the study&#xD;
             endpoints.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmar Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeovil District Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Fagotti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gemelli Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Alfieri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gemelli Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Skipworth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Infirmary of Edinburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugh Paterson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason R. Waggoner, PhD</last_name>
    <phone>513-337-8130</phone>
    <email>jwaggon1@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gemelli Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

